T2 Biosystems, Inc. is a company specializing in rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The company will be reporting its financial results for the first quarter of 2024 and providing business updates after the market closes on Monday, May 6, 2024. A conference call hosted by company management will begin at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call can access a live and archived webcast of the event on the Investor page of the T2 Biosystems website at www.t2biosystems.com in the Events & Presentations section. To listen to the conference call via phone, participants can dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 160751, approximately ten to five minutes prior to the scheduled start time.
T2 Biosystems is dedicated to improving patient care and reducing costs by enabling clinicians to effectively treat patients faster than ever before with their products such as T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel that utilize proprietary T2 Magnetic Resonance (T2MR) technology. With an active pipeline of future products including U.S T2Resistance Panel, Candida auris test and T
